310px-pharmacie_in_paulista_avenue

German health minister Jens Spahn calls for faster adoption of biosimilars

pharmafile | November 14, 2018 | News story | Research and Development AbbVie, Germany, biosimilars, jens Spahn 

Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of healthcare in Germany.

“Where there is a more affordable alternative at the same quality, we have to use it. Otherwise we won’t be able to sustain the high quality of pharmaceutical supply in Germany,” Spahn said.

Spahn, who has been pointed to as a potential successor to Angela Merkel, called for the faster adoption of the biological copies, after it was revealed that biosimilars would have saved the healthcare system €279 million last year.

The call has coincided with the entrance into the market of biosimilar versions of AbbVie’s Humira, which brought in $18 billion in sales last year.

Louis Goss

Related Content

Medincell and AbbVie enter agreement for development of next-generation injectables

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …

AbbVie to acquire Landos Biopharma for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …

AbbVie and Tentarix collaborate on oncology and immunology treatments

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on …

Latest content